NCT07241546 Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma
| NCT ID | NCT07241546 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Arrowhead Pharmaceuticals |
| Condition | Asthma |
| Study Type | INTERVENTIONAL |
| Enrollment | 36 participants |
| Start Date | 2026-03-30 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 36 participants in total. It began in 2026-03-30 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.
Eligibility Criteria
Inclusion Criteria: * Clinically stable, mild atopic asthma (FEV1 ≥70% predicted) * Established allergy confirmed by positive skin prick test at screening * Willing and able to perform lung function tests and other study-related procedures * Participants of childbearing potential must consent to use a method of highly-effective contraception in addition to a condom during the study and for at least 90 days following the end of study or last investigational product administration, whichever is later Exclusion Criteria: * Concomitant diagnosis of a clinically important pulmonary disease other than asthma * Use of corticosteroids, immunosuppressives, or anti-inflammatory medications that interfere with inhaled challenges or inflammation, or chronic use of any other medication for treatment of allergic asthma * History or current medical condition contraindicating methacholine challenge Note: Additional inclusion/exclusion criteria may apply per protocol.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07241546 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Asthma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07241546 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07241546 currently recruiting?
Yes, NCT07241546 is actively recruiting participants. Contact the research team at ARORAGE-2001@arrowheadpharma.com for enrollment information.
Where is the NCT07241546 trial being conducted?
This trial is being conducted at Vancouver, Canada, Calgary, Canada.
Who is sponsoring the NCT07241546 clinical trial?
NCT07241546 is sponsored by Arrowhead Pharmaceuticals. The trial plans to enroll 36 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.